The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO
BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ — SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.
Fourth Quarter 2025 Preliminary Unaudited Financial Results
- Revenue of at least $21 million, representing an increase of approximately 20% year-over-year
- Performed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing 16% year-over-year growth
Full Year 2025 Preliminary Unaudited Financial Results
- Revenue of approximately $77 million, representing an increase of approximately 18% year-over-year
- Performed over 391,000 analyses on SOPHiA DDM™ in 2025, a new company record
“2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth,” said Jurgi Camblong, Chief Executive Officer of SOPHiA GENETICS. “Our strong performance in 2025 positions us well for continued growth in 2026 and beyond. Growth catalysts for the year ahead include our best-in-class Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDM™, valuable opportunities in the U.S. market, and a reinvigorated BioPharma business. We look forward to continuing to demonstrate operating leverage in 2026 and have high confidence in a material improvement in our financial position.”
Full Year 2026 Guidance
Based on information as of today, SOPHiA GENETICS is providing the following FY 2026 guidance:
- Full year revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth
- Adjusted EBITDA loss between $29 million and $32 million
Executive Transition Plan
SOPHiA GENETICS today announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a key executive at the …